For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Tafamidis and the formulated version represents a significant change. These groundbreaking therapies stabilize the transthyretin protein, preventing its harmful build-up and lessening the severity of the condition . People are now rep